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ABSTRACT 
 
Trophoblast cells migrate from the placenta into the endocervical canal early in 
the first trimester and can be collected non-invasively by transcervical sampling 
(TCS), potentially providing fetal DNA for prenatal genetic diagnosis.  
Experiments were conducted to separate fetal cells from maternal cells within the 
TCS specimens and use the fetal cells to perform genetic analysis.  Trophoblast 
cells were efficiently isolated from TCS specimens during weeks 5-18 of 
gestation using HLA-G antibody coupled to magnetic nanoparticles.  
Immunofluorescence microscopy revealed that 99% of isolated cells expressed 
the chorionic gonadotropin β subunit (β-CG), while the non-bound cell fraction 
expressed none.  Immunomagnetically isolated cells from 20 patient specimens 
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were used to determine fetal gender in single cell assays, amplifying sequences 
in genes on the X (DMD) and Y (SRY) chromosomes by multiplex polymerase 
chain reaction (PCR).  Of 270 total cells, PCR products were detected in 256 
cells and identified gender (11 male; 9 female) without error.  PCR-based genetic 
testing is highly reliable as early as week 5 of gestation after immunomagnetic 
isolation of extravillous trophoblast cells obtained by TCS.   
 
INTRODUCTION 
 
Prenatal genetic diagnosis is an appropriate course of action to take in a 
pregnancy when it is known that one of the biological parents has a genetically 
inheritable disease or when the biological mother’s age is so advanced that it 
may introduce genetic abnormalities to the embryo.  In fact, there is a 3% to 5% 
chance that an infant will be born with a chromosomal abnormality or a structural 
defect (O’Leary et al., 2006).  Yet, as of now, there are many limitations as to 
how genetic testing can take place.  The earliest that genetic testing can be done 
is in the first trimester after 10 to 12 weeks of pregnancy using chorionic villus 
sampling (CVS).  It is not the most reliable method, and it puts the woman at risk 
for infection or a 2% chance of miscarriage (Mujezinovic and Alfirevic, 2007).  
There is also evidence that CVS can cause preeclampsia, a condition some 
pregnant women develop in which their blood pressure increases and excess 
protein is found in their urine (Silver et al., 2005).  Preeclampsia can be fatal to 
both the mother and the baby, and it typically necessitates an early delivery with 
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prematurity.  An alternative method to CVS is amniocentesis.  Amniocentesis can 
only be performed in the second trimester between the woman’s 15th and 20th 
week of pregnancy.  It is also an invasive method that puts the pregnancy at a 
1.9% chance of miscarriage (Mujezinovic and Alfirevic, 2007).  Operator 
experience is a major factor in safety (Wapner, 2005), and the risk of pregnancy 
loss is usually less than 1% with an experienced physician. 
 
Through this research project, an alternative method for prenatal genetic 
diagnosis was explored.  This method is based on a non-invasive method that 
can be performed earlier on in the pregnancy (Imudia et al., 2009).  Cervical 
specimens similar to those collected for a PAP smear contain mostly cells shed 
from the endocervical canal.  However, during weeks 6-14 of pregnancy, 
trophoblast cells migrating from the placenta reside in the cervix and can be 
identified by their expression of embryo-specific proteins, including HLAG 
(Imudia et al., 2010).  Time was taken to develop an isolation technique for 
separating HLAG positive cells from HLAG negative cells using a trophoblast cell 
line capable of HLAG expression.  The method developed uses specific 
antibodies bound to magnetic nanoparticles to isolate the trophoblast cells, which 
have now been successfully isolated them from actual cervical specimens for 
genetic testing of the fetus.  This provides the mother with an earlier time frame 
to decide how to handle her pregnancy if an embryonic genetic or chromosomal 
abnormality does show up.  It will also eliminate the risk of miscarriage, as it is a 
non-invasive technique.   
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These experiments were proposed to demonstrate proof-of-principle that 
isolation of trophoblast cells is indeed possible when combined with an excess of 
different cells to simulate a cervical sample and that single-cell methodology can 
be used to assess the purity and fetal origin of isolated trophoblast cells by DNA 
fingerprinting. 
 
Initially, a human trophoblast cell line (HTR) was used to isolate cells expressing 
an embryo-specific protein from a solution containing an excess of cells that lack 
the protein.  Once this method was developed, multiple cervical samples 
collected from clinics that our lab collaborates with were used to demonstrate 
that the method is feasible using actual cervical samples.  Once the cervical 
samples were collected from patients in the clinics, the samples were fixed in the 
lab using Methanol Acetic Acid to prevent the cells from changing between the 
time samples were received and the time that they were tested.  After the cells 
were fixed, they were separated based on their expression of HLAG.  The cells 
were incubated with magnetic beads that have HLAG antibody coupled to their 
surface.  Thus, all of the HLAG positive cells became bound to the magnetic 
beads, and the HLAG negative cells remained free of beads.  The cell mixture 
was then magnetized, the idea being that all of the bead-bound cells should be 
attracted towards the magnet.  Discarding the supernatant and sufficiently 
washing the cells bound to the magnet obtained a pure sample of HLAG positive 
cells.  This method was tested using cultured trophoblast cells that were forced to 
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express HLAG.  The method was tested again by immunofluorescence labeling 
with antibody against beta-HCG using cells that were recovered by 
immunomagnetic separation.  Only human trophoblast cells express beta-hCG 
and should have bind the antibody.  This experiment allowed the establishment 
of whether or not embryonic cells could be separated from maternal cells within 
an actual cervical sample and determined the purity and recovery (both in terms 
of percentage) of the HLAG positive cells when compared to the expected ratio.  
In preliminary studies, cervical samples collected from pregnant patients between 
weeks 7-10 were analyzed by beta-hCG immunofluorescence.  A majority of 
trophoblast cells were recovered, and beta-hCG testing was 100% positive (as 
shown by the table below) proving that the cells recovered were indeed 
uncontaminated and HLAG positive. 
 
Table 1.  Trophoblast isolation from cervical specimens.  Two specimens collected from pregnant 
patients between Weeks 7-10 were analyzed by immunohistochemistry to determine trophoblast frequency 
(HLA-G+ :Total cells) and predict the number of trophoblast cells expected from the total number used.  
Approximately 10% of the specimens were processed by immunomagnetic affinity isolation to purify 
trophoblast cells.  Isolated cells were counted for comparison with the number of trophoblast cells expected.  
Aliquots of the separated Bound cells and Non-bound cells from Samples# 8.4 and 8.25 were labeled with 
anti-β-hCG to determine the percentage of cells expressing the trophoblast-specific protein in each group. 
 
Sample 
ID 
Trophoblast 
Frequency 
No.  
Cells 
Process
ed 
No.  Cells 
Expected 
No.  
Cells 
Isolated 
Trophobla
st 
Recovery 
β-hCG + 
Bound Cells 
β-hCG + 
Non-Bound 
Cells 
8.4 1:1446 500,000 346 365 105% 100% 0% 
8.25 1:1860 240,000 129 78 60% 100% 0% 
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MATERIALS AND METHODS 
 
Separating cells based on an embryo-specific marker. 
A human trophoblast cell line (HTR) was used to demonstrate that it is possible 
to isolate cells expressing an embryo-specific protein from a solution containing 
an excess of cells lacking that protein.  The HTR cell line was cultured using two 
different methods.  The HTR cell line was cultured on fibronectin and matrigel, 
respectively, both basement membranes.  Fibronectin does not affect the HTR 
cells, while Matrigel forces them to express HLAG (human leukocyte antigen G), 
which is only expressed by embryonic cells.  Cervical specimens collected from 
pregnant women during the first trimester contain both maternal (cervical) and 
embryonic (trophoblast) cells.  Thus, a mock cervical specimen was created as 
represented by the HLAG positive and HLAG negative trophoblast cells.  After 
the cells were cultured, the cells were fixed and permeabilized.  The HLAG 
positive cells were then stained with propidium iodide, a fluorescent red nuclear 
stain.  The HLAG negative cells were stained with DAPI, a fluorescent blue 
nuclear stain.  The cells were then be counted and mixed together in a 1:2000 
HLAG positive to negative ratio.  This ratio is consistent with the ratio of 
embryonic cells to maternal cells that are collected from cervical samples (Imudia 
et al., 2009).  Once the cells were combined, they were separated based on their 
expression of HLAG.  The mixture of cells was incubated with magnetic beads 
that had HLAG antibody coupled to their surface.  Thus, all of the HLAG positive 
cells were bound to the magnetic beads, and the HLAG negative cells remained 
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free of beads.  The cell mixture was then magnetized, the idea being that all of 
the bead-bound cells should be attracted towards the magnet.  By discarding the 
supernatant and sufficiently washing the cells bound to the magnet, it became 
possible to obtain a pure sample of HLAG positive cells.  The success of this 
separation was determined by fluorescence microscopy, which identified cells 
labeled with propidium iodide or DAPI.  If only a red fluorescent stain was visible, 
that meant the HLAG positive cells were pure.  A blue fluorescent stain should 
not have been visible, as it would indicate that the isolated cells were impure.  
After undergoing this experiment, it was determined that the separation was 
indeed pure. This experiment established that embryonic cells could be 
separated from maternal cells based on HLAG expression. The purity and 
recovery (both in terms of percentage) of the HLAG positive cells was also 
determined by this experiment.  In preliminary studies, this approach was used 
with a total of 100,000 cells containing 50 HLAG positive cells, and was able to 
recover approximately 10-20% of the HLAG positive cells free of contaminating 
HLAG negative cells.  Recovery was not increased, and it was determined at a 
later point that this was because cells induced to express HLAG slowly and 
steadily lost their HLAG expression.  When the experiment was repeated using 
trophoblast cells derived from transcervical specimens, recovery peaked at 95-
100%. 
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X and Y chromosome assessment of isolated cells and preliminary 
experiments using HTR and fibroblast cells to refine method of PCR and 
storage. 
Since the method being developed revolved around using a single-cell approach 
to conduct genetic testing, single-cell PCR was the first technique to be refined.  
Cells were diluted down until very low concentrations of cells or single cells were 
present in small volumes of RNase free water.  Cells were then heated to boiling 
point in a PCR tube with RNase free water using a heating block, which lysed the 
cells to release the genomic DNA. Immunomagnetically isolated cells from these 
samples were used to conduct single cell assays by amplifying sequences in 
genes on the X (DMD) and Y (SRY) chromosomes by multiplex polymerase 
chain reaction (PCR).  Preliminary steps have been taken and correct amplified 
products can be seen from single-cell PCR.  Single bands were visible at the site 
of the X amplicon for HTR cells, which are female.  The fibroblast cell line, 
derived from human foreskin, generated two bands representing both X and Y 
amplicons.  This experiment ensured accurate results through PCR.  Thus, when 
immunomagnetically isolated cells from 20 patient specimens were used to 
determine fetal gender in single cell assays, in the 270 total cells, PCR products 
were detected in 256 (95%) and identified gender (11 male; 9 female) without 
error.  It was also vital to determine how the cervical samples would be stored 
before PCR is conducted.  Time trials with single cells from the cell lines were 
conducted to see if PCR needed to be conducted immediately after cervical 
samples are received or whether the cells from the samples could be isolated 
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and stored frozen before conducting PCR.  Based on the PCR results, it was 
determined that storage time did not affect results drastically.  Thus, cervical 
samples were allowed to be frozen before undergoing PCR. 
 
Genetic assessment of DNA using a single-cell approach. 
Genetic assessment of DNA was conducted using the HTR and fetal fibroblast 
cell lines.  Once the genetic assessment of DNA was completed using these 
mock cells, the refined procedure was to work with transcervically derived 
trophoblast cells.  Because the maternal and embryonic cells in a cervical sample 
cannot be differentially labeled before the cell separation procedure, the isolation 
of pure trophoblast cells was further assessed (after completing beta-hCG 
testing) by DNA fingerprinting. Preliminary experiments were carried out to 
optimize DNA analysis protocols before proceeding with pilot cell separation 
experiment using HLAG positive HTR cells and a genetically distinct HLAG 
negative cell line.  Cells in small groups or single cells were lysed for genomic 
DNA isolation and amplification through heating, as there is no commercial kit 
available at the time being that works with such low numbers of cells (similar to 
what was done with single-cell PCR).  The cells were placed in RNase free water 
then boiled in order to lyse the cells and release the genetic content.  Cells were 
lysed for genomic DNA isolation and amplification with the Whole Genome 
Amplification (WGA) Kit (Sigma Aldrich, St. Louis, MO) or Rubicon PicoPlexTM 
WGA (Rubican, Ann Arbor, MI), calculating yields by Nanodrop 
spectrophotometry (Wilmington, DE). DNA was isolated from each cell line to 
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establish their DNA fingerprints.  Next, the whole genome amplification 
procedure was piloted with decreasing numbers of cells, down to single cells, 
followed by DNA fingerprinting.  DNA was then fingerprinted using the 
AmpFlSTR Identifiler PCR Amplification kit (ABI) that was developed in 
accordance with forensic standards (Collins et al., 2004).  As two different cell 
lines were used initially, the DNA fingerprints should have been different.  If the 
fingerprints were consistent and differed between cell lines, the testing could be 
progressed from cell lines to transcervical samples.  In this experiment reference 
fingerprints needed to be obtained that would serve as a model for distinguishing 
DNA from the cells.  It was also important to acquire the ability to perform this 
procedure with the small number of cells isolated in the cell separation procedure 
used with cervical specimens.  Despite diligent efforts, this method has not yet 
become feasible for a single-cell approach. The method was however successful 
on as little as 40 cells, which is substantially lower than the average of range of 
thousands of cells that are normally required for this procedure. 
 
RESULTS 
Twenty-six transcervical specimens were obtained from pregnant women with 
fetuses ranging in gestational age between 5 and 18 weeks (Table 2).  Cell 
counts suggested that trophoblast recovery after immunomagnetic isolation 
averaged 101%.  The average percentage of cells expressing β-CG among the 
magnetically bound cells was 99% (range, 95%-100%; Table 2), while none of 
the cells in the excluded, non-bound fraction were β-CG positive.  To further 
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establish that the isolated cells were trophoblast, immunofluorescence 
microscopy was used to examine expression of marker proteins, β-CG, as 
expressed by immunomagnetically isolated cells from transcervical specimens. 
 
Table 2. Trophoblast Content, Recovery and Purity. TCS specimens obtained 
from patients at the indicated gestational ages were examined by IHC for the 
presence of HLA-G and the total number of HLA-G-positive cells in each 
specimen was estimated. Anti-HLA-G-binding cells were isolated with magnetic 
nanoparticles and the total number of cells recovered from each specimen was 
estimated from cell counts, with the percentage of that predicted by IHC shown in 
parentheses. Immunofluorescence microscopy was used to determine the 
number of cells expressing β-CG/total cells examined, with the percentage 
expressing β-CG shown in parentheses. 
	  
Gestational	  Age	  
(weeks.days)	  
#	  HLA-­‐G-­‐
Positive	  Cells	  
#	  Isolated	  Cells	  
(%	  Recovered)	  	  
β-­‐CG	  Reactive	  (%)	  
	  
 5.3 1313 1140 (87) 233/233 (100) 
 6 609 998 (164) 190/200 (95) 
 7 575 593 (103) 118/118 (100) 
 7.3 677 855 (126) 540/542 (99.6) 
 7.4 842 623 (74) 100/102 (98) 
 7.5 314 870 (277) 250/250 (100) 
 7.6 1108 345 (31) 1482/1500(98.8) 
 8 593 510 (86) 250//250 (100) 
 8 1045 728 (70) 93/94 (98.9) 
 8 609 660 (108) 58/58 (100) 
 8 788 848 (108) 69/70 (99) 
 9.2 1260 248 (20) 1485/1500 (99) 
 10 2222 1462 (66) 793/811 (97.8) 
 10 1095 1020 (93) 84/84 (100) 
 11 581 720 (124) 594/598 (99.3) 
 11 1027 622 (61) 250/250 (100) 
 11 529 1463 (277) 181/191 (98.4) 
 12 850 578 (68) 247/250 (98.9) 
 12 879 758 (86) 96/96 (100) 
 12.4 1109 495 (45) 53/55 (96.4) 
 14 820 705 (86) 87/87 (100) 
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 14.6 466 660 (142) 1485/1500 (99) 
 15.2 570 570 (100) 385/387 (99.5) 
 15.4 2467 832 (34) 992/1000 (99.2) 
 17.5 1009 818 (81) 850/853 (99.6) 
 17.6 239 270 (113) 966/970 (99.6) 
Average   10.4 908 746 (101) 99% 
 
 
To establish that trophoblast cells isolated from transcervical specimens were a 
valid source of fetal DNA for single cell prenatal genetic diagnosis, multiplex PCR 
was conducted with replicates of individual frozen cells from 20 patient specimen 
using primers for DMD and SRY to detect the presence of an X (control) or Y 
chromosome, respectively. Male fetuses were readily identified by amplification 
of two bands, while trophoblast cells from female fetuses produced only the X 
band. In addition to individual trophoblast cells, PCR analysis of each specimen 
included single foreskin fibroblasts or isolated foreskin DNA as positive male 
controls. The fetal sex of all 20 pregnancies was correctly determined, as verified 
by delivery records (Table 3). There were nine female and eleven male fetuses 
among the twenty specimens examined. The specificity of the PCR worked well, 
as SRY amplicons were clearly distinguished from DMD amplicons.  Overall, 
there were no visible bands produced by PCR in 14 of 270 cells evaluated 
(5.2%). The PCR-determined genders of individual cells were homogeneous 
within every specimen. 
 
Table 3. Fetal Gender Determination. Anti-HLA-G-bound cells isolated with 
magnetic nanoparticles were assayed by single cell, multiplex PCR for the X and 
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Y chromosome  markers DMD and SRY, respectively.  Five to thirty replicate 
cells from each patient were examined to determine the presence or absence of 
each chromosome, presented as the number of cells that produced an 
amplicon/total cells examined. Genders were verified from birth records. 
Gestational	  Age	  
(weeks.days)	  
X	  Chromosome	  
detected	  (%)	  
Y	  Chromosome	  
detected	  (%)	  
Gender	  
Verification	  
5.3 10/10 (100) 0/10 (0) Female 
6 25/30 (83.3) 0/30 (0) Female 
7.6 25/25 (100) 0/25 (0) Female 
8 10/10 (100) 0/10 (0) Female 
10 10/10 (100) 0/10 (0) Female 
12 10/10 (100) 0/10 (0) Female 
12 9/10 (90) 0/10 (0) Female 
12.4 10/10 (100) 0/10 (0) Female 
17.6 10/10 (100) 0/10 (0) Female 
7.3 5/5 (100) 5/5 (100) Male 
7.5 10/10 (100) 10/10 (100) Male 
8 25/28 (89.3) 25/28 (89.3) Male 
9.2 10/10 (100) 10/10 (100) Male 
10 10/10 (100) 10/10 (100) Male 
11 10/10 (100) 10/10 (100) Male 
12 24/26 (92.3) 24/26 (92.3) Male 
14 6/6 (100) 6/6 (100) Male 
14.6 18/20 (90) 18/20 (90) Male 
15.2 9/10 (90) 9/10 (90) Male 
17.5 10/10 (100) 10/10 (100) Male 
 
 
FUTURE DIRECTIONS 
This method was implemented in all experiments, especially when cervical cell 
samples from pregnant patients obtained by physicians in the Department of 
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Obstetrics & Gynecology were used.  If fingerprinting can be refined for use with 
a single-cell, then it will be establish whether the isolated cells are free of 
maternal DNA, which can easily be determined with a blood sample from the 
mother.  It should be noted, however, that purity of the fetal cells may eventually 
become less important than yield.  New technologies are currently being 
developed that use bioinformatics to distinguish maternal from fetal sequence 
information (Chiu et al., 2008; Jorgez and Bischoff, 2009; Lo et al., 2007; Lun et 
al., 2008). 
 
By completing this study with the use of cervical cell samples from pregnant 
patients that were obtained by physicians in the Department of Obstetrics & 
Gynecology, the non-invasive alternative technique to amniocentesis and CVS 
was further developed.  Fingerprinting will help establish whether the isolated 
cells are free of maternal DNA, which can easily be determined with a blood 
sample from the mother.  With the culmination of this project, there is the hope 
that the investigated non-invasive method will eventually lead to clinical trials. 
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